If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A German research team has demonstrated the link between Thrombospondin Type-1 Domain containing 7A Protein and various cancer types and presents a new way to use this tumor specific to improve cancer treatment efficiency by early diagnosis. Sought are industrial or institutional partners involved in the development and/or production of cancer biomarkers, cancer diagnosis/therapy, and research of cancer treatment for licensing, transfer of rights, knowledge transfer, or R&D cooperation.
The timely medical diagnosis of cancer requires biomarkers which are specific for the different cancer types.
A German research group has revealed a direct link between specific tumor entities and the expression level of Thrombospondin Type-1 Domain containing 7A protein (THSD7A), which can be utilized as a new tumor antigen to increase the predictive value of in-vitro diagnostic and prognostic detection methods for cancer, leading to an optimized early diagnosis and treatment decision.
Immunohistochemistry tests using tissue microarrays were performed on more than 70 tumor entities (including 20.000 tissue spots) and have demonstrated the association between the THSD7A marker and the described tumor entities, e.g. for breast, prostate, renal, and colorectal cancer. Furthermore, THSD7A antibodies are measurable in whole blood, serum, or plasma. This combination makes it a powerful screening tool for tumor identification. For example, in case of the renal disorder Membranous Nephropathy (MN), a concomitant malignancy could be indicated by the presence of THSD7A antibodies.
Additionally, the innovation offers the possibility to treat THSD7A expressing cancer cells selectively with cytotoxic compounds linked to anti-THSD7A antibodies to optimize site directed drug application and minimize therapeutic side effects.
Due to the strong relation to several tumor entities, THSD7A can be considered a robust and multifunctional biomarker making it a helpful tool for personalized medicine in cancer treatment, which shall directly improve patient care through early diagnosis of the disease and better adjustment of therapeutic measures.
Partners could be enterprises or institutions involved in the development and/or production of cancer biomarkers, cancer diagnosis and therapy, research in cancer treatment, Membranous Nephropathy, or in personalized medicine. They could benefit from a transfer of rights of the existing IP (patent pending), licensing, knowledge transfer, or R&D collaborations to test and refine the technology in commercially relevant projects.
The advantages of the invention for tumor screening lies in the combination of easy detection of THSD7A antibodies in serum, plasma, or (whole) blood, and its expression in different relevant neoplasias, e.g. breast, prostate, renal, or colorectal cancer.
In-vitro tumor data
Sought are industrial or institutional partners involved in the development and/or production of cancer biomarkers, cancer diagnosis and therapy, research of cancer treatment, Membranous Nephropathy, or in personalized medicine.
Partners are sought for licensing, transfer of rights (pending patent), or knowledge transfer. The innovation could be tested and refined in commercially relevant projects and R&D cooperation.